We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
story of the week

Journal Scan / Research · May 05, 2021

Sacituzumab Govitecan in Patients With Metastatic Urothelial Carcinoma Progressing After Platinum-Based Chemotherapy and Checkpoint Inhibitors

Journal of Clinical Oncology

 

Additional Info

Journal of Clinical Oncology
TROPHY-U-01: A Phase II Open-Label Study of Sacituzumab Govitecan in Patients With Metastatic Urothelial Carcinoma Progressing After Platinum-Based Chemotherapy and Checkpoint Inhibitors
J. Clin. Oncol 2021 Apr 30;[EPub Ahead of Print], ST Tagawa, AV Balar, DP Petrylak, AR Kalebasty, Y Loriot, A Fléchon, RK Jain, N Agarwal, M Bupathi, P Barthelemy, P Beuzeboc, P Palmbos, CE Kyriakopoulos, D Pouessel, CN Sternberg, Q Hong, T Goswami, LM Itri, P Grivas

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading